- media@moneyinfocus.news
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a $2.9 billion all-cash transaction, reinforcing its strategic expansion into endocrinology and rare disease treatments.
Under the terms of the agreement, Neurocrine will pay $53 per share — representing a premium of approximately 34% over Soleno’s recent closing price.
The acquisition centers on Soleno’s lead therapy, Vykat XR, a treatment for Prader-Willi syndrome — a rare condition characterized by chronic and compulsive hunger.
According to The Wall Street Journal, the drug generated approximately $190 million in revenue in its first year following approval, underscoring strong early commercial traction in a niche but high-value market.
The deal is expected to strengthen Neurocrine’s commercial portfolio and provide access to a differentiated, first-in-class therapy with long-term growth potential. Vykat XR is also supported by intellectual property protections extending into the mid-2040s, reinforcing its durability as a revenue-generating asset.
Neurocrine plans to fund the transaction primarily through cash on hand, complemented by a modest level of debt, with completion anticipated in the coming months.
The transaction reflects a broader acceleration in biotechnology dealmaking, as companies increasingly target rare disease platforms with proven therapies and scalable pipelines.
As reported by The Wall Street Journal, the acquisition aligns with a surge in sector activity, with tens of billions of dollars in biotech deals already recorded in early 2026.
